SEARCH

SEARCH BY CITATION

REFERENCES

  • Barton GR, Bankart J, Davis AC, Summerfield QA. 2004. Comparing utility scores before and after hearing-aid provision. Applied Health Economics and Health Policy 3(2): 103105.
  • Brazier J, Czoski-Murray C, Roberts J, Brown M, Symonds T, Kelleher C. 2008. Estimation of a preference-based index from a condition-specific measure: the King's Health Questionnaire. Medical Decision Making 28(1): 113126.
  • Brazier JE, Ratcliffe J, Tsuchiya A, Solomon J. 2007. Measuring and Valuing Health for Economic Evaluation. Oxford University Press: Oxford.
  • Brazier JE, Roberts J, Platts M, Zoellner YF. 2005. Estimating a preference-based index for menopausal specific health related quality of life questionnaire. Health and Quality of Life Outcomes 3:13.
  • Brazier JE, Tsuchiya A, Rowan D, Yang Y, Young T. 2009. Developing preference-based condition specific measures: why, when, how and do you achieve comparability between measures? Health Economics and Decision Science Discussion Paper 01/09, University of Sheffield, Sheffield, UK.
  • Brooks R, EuroQol Group. 1996. EuroQol: the current state of play. Health Policy 37: 5372.
  • Dolan P. 1997. Modelling valuations for EuroQol health states. Medical care 35(11):10951108.
  • Dowie J. 2002. Decision validity should determine whether generic or condition-specific HRQOL measure is used in health care decisions. Health Economics 11: 18.
  • Espallargues M, Czoski-Murray C, Bansback N, Carlton J, Lewis G, Hughes L, Brand C, Brazier J. 2005. The impact of Age Related Macular Degeneration on health state utility values. Investigative Ophthalmology and Visual Science 46: 40164023.
  • Feeny D, Furlong W, Torrance GW et al. 2002. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Medical Care 40: 113128.
  • Food and Drug Administration. 2006. Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labelling claims. U.S. Department of Health and Human Services. February. http://www.fda.gov/cder/guidance/5460dft.htm.
  • Gold MR, Siegel JE, Russell LB, Weinstein MC. 1996. Cost-Effectiveness in Health and Medicine. Oxford University Press: Oxford.
  • Gray A, Rivero-Arias O, Clarke PM. 2006. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Medical Decision Making 26: 1829.
  • Haywood KL, Garratt AM, Lall R, Smith JF, Lamb SE. 2008. EuroQol EQ-5D and condition specific outcome measures in women with urinary incontinence: reliability, validity and responsiveness. Quality of Life Research 17(10): 475483.
  • Kok ET, McDonnell J. 2002. The valuation of the International Prostate Symptom Score (IPSS) for the use in economic evaluations. European Urology 42: 491497.
  • National Institute for Clinical Excellence. 2008. Guide to the Methods Technology Appraisal. NICE: England.
  • Revicki DA, Leidy NK, Brennan-Diemer F, Sorenson S, Togias A. 1998. Integrating patients preferences into health outcomes assessment: the multiattribute asthma symptom utility index. Chest 114(4): 9981007.
  • Torrance GW, Keresteci MA, Casey RW, Rosner AJ, Ryan N, Breton MC. 2004. Development and testing of a new preference-based disease-specific health-related quality of life instruments for erectile function. Quality of Life Research 13: 349359.
  • Walters S, Morrell C, Dixon S. 1999. Measuring health-related quality of life in patients with venous leg ulcers. Quality of Life Research 8(4): 327336.
  • Williams A. 1995. The measurement and valuation of health: a chronicle. Centre for Health Economics, Discussion Paper, University of York.
  • Yang Y, Tsuchiya A, Brazier J, Young T. 2006. Deriving a Preference-based Measure for Health from the AQLQ. HESG, City University, January.